Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases. It targets molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
Type | Public | |
Founded | 2002 | |
HQ | Plano, TX, US | Map |
Website | reatapharma.com | |
Employee Ratings | More | |
Overall Culture | B | More |
USD | |
---|---|
Revenue (FY, 2020) | 9.0m |
Net income (FY, 2020) | (247.8m) |
Market capitalization (30-Mar-2021) | 3.5b |
Closing stock price (30-Mar-2021) | 97.1 |
Cash (31-Dec-2020) | 818.2m |
USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|
Revenue | 32.4m | 7.6m | 5.2m | 7.8m | 7.8m | 8.2m | 1.4m | 3.1m | 1.4m |
General and administrative expense | 6.6m | 10.7m | 7.5m | 10.0m | 11.7m | 14.3m | 20.8m | 16.6m | 18.3m |
R&D expense | 21.4m | 23.4m | 27.1m | 26.1m | 29.6m | 32.3m | 47.7m | 36.8m | 37.2m |
Operating expense total | 28.1m | 34.2m | 34.7m | 36.3m | 41.5m | 46.8m | 68.7m | 53.7m | 55.8m |
USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|
Net Income | 4.1m | (24.1m) | (55.0m) | (29.2m) | (63.5m) | (103.2m) | (48.9m) | (116.5m) | (182.0m) |
Depreciation and Amortization | 101.0k | 206.0k | 311.0k | 170.0k | 401.0k | 659.0k | 278.0k | 562.0k | 851.0k |
Accounts Payable | (1.1m) | 46.0k | 2.9m | (522.0k) | 312.0k | (440.0k) | 10.7m | 9.4m | 7.0m |
Cash From Operating Activities | (24.0m) | (49.4m) | (46.3m) | (28.7m) | (61.4m) | (101.8m) | (41.2m) | (237.1m) | (277.2m) |
USD | FY, 2017 |
---|---|
Revenue/Employee | 516.8k |
Debt/Equity | -0.1 x |
Debt/Assets | 0.1 x |
Financial Leverage | -0.9 x |
FY, 2016 | |
---|---|
Patents Issued | 240 |
Patents Pending | 280 |
Phase I Trials Products | 2 |
Phase III Trials Products | 1 |
Reata Pharmaceuticals revenue breakdown by business segment: 95.3% from License and Milestone and 4.7% from Other
Reata Pharmaceuticals has 1.1k Twitter Followers. The number of followers has increased 2.5% month over month and increased 8.7% quarter over quarter
945
Tweets
506
Following
1.1k
Followers
22
Tweets last 30 days
6
Avg. likes per Tweet
100%
Tweets with engagement
B
81/100
A-
80/100
A+
95/100
When was Reata Pharmaceuticals founded?
Reata Pharmaceuticals was founded in 2002.
Who are Reata Pharmaceuticals key executives?
Reata Pharmaceuticals's key executives are Warren Huff, Dawn C. Bir and Colin Meyer.
How many employees does Reata Pharmaceuticals have?
Reata Pharmaceuticals has 220 employees.
What is Reata Pharmaceuticals revenue?
Latest Reata Pharmaceuticals annual revenue is $9 m.
What is Reata Pharmaceuticals revenue per employee?
Latest Reata Pharmaceuticals revenue per employee is $41 k.
Who are Reata Pharmaceuticals competitors?
Competitors of Reata Pharmaceuticals include Apellis Pharmaceuticals, Alnylam Pharmaceuticals and Ionis Pharmaceuticals.
Where is Reata Pharmaceuticals headquarters?
Reata Pharmaceuticals headquarters is located at 5320 Legacy Dr, Plano.
Where are Reata Pharmaceuticals offices?
Reata Pharmaceuticals has offices in Plano and Irving.
How many offices does Reata Pharmaceuticals have?
Reata Pharmaceuticals has 3 offices.
Receive alerts for 300+ data fields across thousands of companies